By Sneha S K June 6 (Reuters) - Medical device maker Dexcom said the use of its continuous glucose monitor, G7, led to ...

Dexcom anticipates that the findings could drive a shift in the standard of care for type 2 diabetes patients who do not use ...

Customers have known for months that the Dexcom G7 continuous glucose monitoring sensor had problems. Now, the company is ...

A new study presented at the American Diabetes Association found that Dexcom’s G7 continuous glucose monitor significantly ...

In the lead-up to the American Diabetes Association’s Scientific Sessions, Dexcom announced an acquisition and Insulet rolled ...

MyLife Diabetes Care, CamDiab and Dexcom today announced the integration of the G7 continuous glucose monitor (CGM) into the ...

San Diego device maker Dexcom has received the first FDA clearance for a continuous glucose monitor that doesn’t require a doctor’s prescription. The U.S. Food and Drug Administration cleared Dexcom’s ...

Dexcom says stolen G7 sensors from two scrapped lots were sold through unauthorized channels, creating infection and reading-failure risks.

Abbott Laboratories (NYSE: ABT) and Dexcom (NASDAQ: DXCM) are two leading medical device companies that compete against one another in the market for continuous glucose monitoring (CGM) systems. They ...

Hunterbrook Media released a short report on diabetes-focused DexCom Inc. (NASDAQ:DXCM), citing that the company sold the "adulterated" device. Benzinga reached out to DexCom for comments and is yet ...

DexCom is a medical device leader that develops and markets continuous glucose monitoring (CGM) systems to track blood glucose levels in real time. DexCom is a leader in this niche. And while some ...